{"gene":"CLN5","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1998,"finding":"CLN5 was identified as a novel gene encoding a putative transmembrane protein underlying Finnish variant late infantile neuronal ceroid lipofuscinosis (vLINCL), with three disease-causing mutations (one deletion, one nonsense, one missense) identified by positional cloning and sequence analysis.","method":"Positional cloning, linkage analysis, mutation sequencing","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1 — original positional cloning with multiple mutations identified, foundational paper with 224 citations","pmids":["9662406"],"is_preprint":false},{"year":2002,"finding":"CLN5 protein localizes predominantly to lysosomes and is a soluble lysosomal glycoprotein (~60 kDa, reduced to ~40 kDa by deglycosylation), not an integral transmembrane protein as originally predicted; the most common human vLINCL mutation blocks lysosomal targeting.","method":"Confocal immunofluorescence microscopy, immunoprecipitation, deglycosylation assays, transient transfection in BHK-21 cells","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal biochemical and imaging methods in single study, 100 citations","pmids":["11971870"],"is_preprint":false},{"year":2002,"finding":"CLN5 protein directly interacts with CLN2 and CLN3 proteins; CLN5 is synthesized as four precursor forms due to alternative initiator methionines, all targeted to lysosomes, with the longest membrane-associated form mediating interactions with CLN2 and CLN3; disease mutations in CLN5 abolished interaction with CLN2 but not CLN3.","method":"Coimmunoprecipitation, in vitro binding assays, western blotting","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal Co-IP plus in vitro binding, multiple isoforms characterized, 90 citations","pmids":["12134079"],"is_preprint":false},{"year":2009,"finding":"CLN5 interacts with multiple NCL proteins (CLN1/PPT1, CLN2/TPP1, CLN3, CLN6, CLN8); overexpression of PPT1 can facilitate lysosomal transport of mutated CLN5 normally retained in ER/Golgi; CLN5 also binds F1-ATPase, a known PPT1 binding partner.","method":"Coimmunoprecipitation, confocal microscopy, overexpression studies","journal":"BMC cell biology","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple Co-IP interactions confirmed, functional rescue experiment with PPT1 overexpression","pmids":["19941651"],"is_preprint":false},{"year":2012,"finding":"CLN5 interacts with the lysosomal sorting receptor sortilin; CLN5 depletion causes degradation of lysosomal sorting receptors sortilin and CI-MPR due to defective retromer recruitment at endosomes, linked to reduced active (GTP-loaded) Rab7 levels.","method":"Coimmunoprecipitation, siRNA knockdown in HeLa cells, western blotting, immunofluorescence","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, KD with defined molecular phenotype, multiple orthogonal methods, 67 citations","pmids":["22431521"],"is_preprint":false},{"year":2013,"finding":"All eight N-glycosylation sites of CLN5 are utilized in vivo; glycosylation at N179, N252, N304, or N320 is required for proper protein folding (mutation causes ER retention), while N401 glycosylation is essential for lysosomal trafficking but not folding.","method":"Site-directed mutagenesis of individual Asn residues, localization studies by immunofluorescence, western blotting","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis of all 8 sites with functional readouts, 51 citations","pmids":["24058541"],"is_preprint":false},{"year":2013,"finding":"CLN5 is synthesized as a type II transmembrane glycoprotein with cytoplasmic N-terminus, one TM segment, and a large luminal C-terminal domain containing an amphipathic helix (AH); cytoplasmic and TM domains are removed after signal peptide cleavage; the AH anchors mature CLN5 to the membrane lumen; CLN5 pathological mutants lacking AH are retained in the ER and degraded by the proteasome.","method":"Epitope-tagged CLN5 topology determination, protease protection assay, mutagenesis, immunofluorescence, proteasome inhibition","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 1 — systematic topology mapping with mutagenesis and functional consequences, 16 citations","pmids":["24038957"],"is_preprint":false},{"year":2015,"finding":"CLN5 undergoes proteolytic C-terminal cleavage post-translationally in an acidic compartment, likely by a cysteine protease; two forms (~60 and ~56 kDa) are present in cells; processing occurs beyond the ER and can initiate from the trans-Golgi network.","method":"Cycloheximide chase analysis, pharmacological inhibition of proteases, transient transfection, western blotting","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 — multiple pharmacological inhibitors used, kinetic pulse-chase, but no direct identification of the protease","pmids":["26342652"],"is_preprint":false},{"year":2017,"finding":"CLN5 is cleaved by SPPL3 (a member of the SPP/SPPL intramembrane protease family), generating a mature soluble protein consisting of residues 93-407; the remaining N-terminal fragment is then cleaved by SPPL3 and SPPL2b and degraded by the proteasome.","method":"Overexpression of SPPL family members, inhibitor studies, western blotting, immunofluorescence","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 — specific protease identified with functional validation, 25 citations","pmids":["28442266"],"is_preprint":false},{"year":2017,"finding":"Both Dictyostelium Cln5 and human CLN5 function as glycoside hydrolases, providing the first molecular enzymatic function attributed to CLN5; Dictyostelium Cln5 is secreted during growth and starvation; Cln5 immunoprecipitation identified 61 interacting proteins enriched for metabolic, catabolic, and hydrolytic functions including NCL-like proteins.","method":"Glycoside hydrolase enzymatic assay, immunoprecipitation coupled with mass spectrometry, localization by fluorescence microscopy, secretion assay","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 1-2 — in vitro enzymatic assay demonstrated for both Dictyostelium and human CLN5, 45 citations","pmids":["29128403"],"is_preprint":false},{"year":2018,"finding":"A CLN5 missense variant (p.Asn320Ser) linked to Alzheimer's disease causes glycosylation defects leading to ER retention of CLN5 and reduced delivery to endolysosomal compartment; this variant reduces normal cathepsin D processing and decreases full-length APP levels, consistent with a retromer trafficking defect.","method":"Expression of mutant protein, glycosylation analysis, immunofluorescence localization, western blotting for cathepsin D maturation and APP levels","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional readouts in a single study linking CLN5 mutation to retromer and cathepsin D processing","pmids":["30037983"],"is_preprint":false},{"year":2021,"finding":"CLN5 and CLN3 function as an endolysosomal complex; CLN5 deletion causes retromer dysfunction and impaired endolysosome fusion, leading to delayed degradation of endocytic proteins and defective autophagy; CLN5 regulates CLN3 interactions with RAB7A and a subset of RAB7A effectors.","method":"CRISPR knockout, Co-IP, endosome fusion assays, western blotting, immunofluorescence","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods defining CLN5-CLN3 complex and downstream RAB7A pathway, 25 citations","pmids":["34060589"],"is_preprint":false},{"year":2022,"finding":"CLN5 (Cln5) crystal structure was solved and revealed a region homologous to the catalytic domain of N1pC/P60 superfamily papain-like enzymes; CLN5 has cysteine palmitoyl thioesterase (S-depalmitoylation) activity; the catalytic residues histidine-166 and cysteine-280 are critical for this activity; CLN5-deficient neuronal progenitor cells showed reduced thioesterase activity.","method":"X-ray crystallography, fluorescent substrate thioesterase assay, active-site mutagenesis, cell-based thioesterase activity assay","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1 — crystal structure, in vitro enzymatic assay, mutagenesis, and cellular functional validation in single study","pmids":["35427157"],"is_preprint":false},{"year":2022,"finding":"The CRL3-KCTD7 E3 ubiquitin ligase complex ubiquitinates CLN5 targeting it for proteasomal degradation; NCL patient-derived KCTD7 mutations disrupt KCTD7-CLN5 interaction causing CLN5 accumulation in the ER; excess CLN5 disrupts CLN6/CLN8 interaction with lysosomal enzymes, impairing ER-to-Golgi trafficking of lysosomal enzymes.","method":"Co-IP, ubiquitination assays, KCTD7 knockout cells, western blotting, immunofluorescence","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1-2 — ubiquitination assay plus Co-IP plus functional trafficking readout, mechanistically placing CLN5 as CRL3-KCTD7 substrate","pmids":["35921411"],"is_preprint":false},{"year":2023,"finding":"CLN5 is the lysosomal BMP (bis(monoacylglycero)phosphate) synthase; CLN5-deficient cells show massive accumulation of the BMP synthesis precursor LPG and depletion of BMP species; CLN5 mediates BMP synthesis through an energy-independent base exchange reaction between two LPG molecules, with increased activity on BMP-laden vesicles.","method":"Lipidomics of CLN5 knockout cells, in vitro enzymatic reconstitution with purified protein, lipid mass spectrometry","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic reconstitution demonstrating BMP synthase activity, lipidomics validation in KO cells, 55 citations","pmids":["37708259"],"is_preprint":false},{"year":2023,"finding":"QM/MM computational analysis confirmed the catalytic triad Cys280-His166-Glu183 is critical for CLN5 S-depalmitoylation activity; the S-depalmitoylation step is rate-limiting with a barrier of ~26.1 kcal/mol; this study defined the atomic-level reaction mechanism.","method":"QM/MM molecular dynamics at ωB97X-D/6-31G(d,p):AMBER level, NBO charge analysis, local mode force constants","journal":"Journal of the American Chemical Society","confidence":"Medium","confidence_rationale":"Tier 4 (computational) — high-level QM/MM study confirming previously crystallographically and experimentally established catalytic residues","pmids":["38055807"],"is_preprint":false},{"year":2010,"finding":"CLN5 is proteolytically cleaved to produce a mature polypeptide trafficked to lysosomes; CLN5 can undergo mannose-6-phosphate receptor-independent trafficking to lysosomes; all analyzed disease mutations disturb lysosomal trafficking of CLN5 but the degree of lysosomal targeting does not correlate with disease onset, suggesting CLN5 may also function outside lysosomes.","method":"Stable and transient expression, immunofluorescence localization, western blotting, treatment with M6P receptor inhibitors","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 — stable expression systems with multiple mutants, M6P-independent trafficking demonstrated pharmacologically","pmids":["20052765"],"is_preprint":false},{"year":2012,"finding":"CLN5-deficient fibroblasts show reduced ceramide, sphingomyelin, and glycosphingolipid levels; CLN8 protein corrects growth and apoptosis defects in CLN5-deficient cells; co-immunoprecipitation with CerS1 and absence of γ-actin from the CerS1 protein complex in CLN5-deficient cells suggest CLN5 functions as an activator of ceramide synthases.","method":"Lipid mass spectrometry, co-immunoprecipitation, differential gel electrophoresis, complementation assays","journal":"Electrophoresis","confidence":"Low","confidence_rationale":"Tier 3 — single Co-IP, complementation data suggestive but indirect for CLN5 as ceramide synthase activator","pmids":["23160995"],"is_preprint":false},{"year":2020,"finding":"CLN5 loss causes impairment of mitochondrial functions; a mitochondria-focused quantitative proteomics approach revealed impaired autophagy machinery and altered mitophagy activation; these mitochondrial defects were confirmed in CLN5 KO cell models and Cln5-/- cerebral cortex and correlated with disease progression.","method":"Quantitative proteomics (mitochondria-enriched fractions), immunofluorescence, mitochondrial respiration assays, flow cytometry, patient fibroblast validation","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 — quantitative proteomics plus functional assays across multiple models, 28 citations","pmids":["32257390"],"is_preprint":false},{"year":2021,"finding":"CLN5-deficient human neurons (generated by CRISPRi in iPSC-derived cortical neurons) show reduced acidic organelles, reduced lysosomal enzyme activity, and impaired lysosomal movement — the first report of lysosomal trafficking defects in CLN5 disease.","method":"CRISPRi knockdown, live microscopy, flow cytometry, lysosomal enzyme activity assays, lysosomal tracking","journal":"Biomolecules","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPRi KD in human neurons with multiple functional readouts in a relevant cell type","pmids":["34680045"],"is_preprint":false},{"year":2004,"finding":"The mouse Cln5 gene product is a soluble lysosomal glycoprotein expressed in the developing brain, with prominent expression in cerebellar Purkinje cells, cerebral neurons, and hippocampal cells; expression pattern correlates with CNS regions that degenerate in CLN5 patients.","method":"In situ hybridization, immunohistochemistry, in vitro expression in COS-1, HeLa, and neuronal cells","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization by immunohistochemistry plus in vitro expression characterization, 53 citations","pmids":["15207259"],"is_preprint":false},{"year":2004,"finding":"Cln5-/- mice show loss of vision, accumulation of autofluorescent storage material in CNS and peripheral tissues, prominent loss of GABAergic interneurons in multiple brain areas, and downregulation of myelin structural components; transcript profiling revealed altered expression of genes involved in neurodegeneration and immune/defense responses.","method":"Targeted gene deletion (exon 3), electron microscopy, immunohistochemistry, transcript profiling","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — clean KO mouse model with defined cellular phenotypes across multiple brain regions, 71 citations","pmids":["15459177"],"is_preprint":false},{"year":2011,"finding":"Cln5 deficiency in mice leads to early and significant microglial activation (by 3 months), defective myelination in vitro and in developing brain, early alterations in serum lipid profiles, and dysfunctional lipid transport; Cln5 is most highly expressed in microglia.","method":"Gene expression analysis, in vitro myelination assays, microglial activation immunostaining, serum lipid profiling","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays in Cln5 KO model with mechanistic readouts, 43 citations","pmids":["22182690"],"is_preprint":false},{"year":2019,"finding":"Loss of Cln5 in mice results in increased neural progenitor cell (NPC) proliferation, reduced NPC migration, and increased neuronal differentiation; neurite outgrowth was compromised in Cln5-/- cortical neurons; impaired interneuron development was linked to increased REST/NRSF binding to the Gad1 locus, reducing GAD67 (rate-limiting enzyme in GABA synthesis) expression.","method":"Embryonic brain analysis, BrdU proliferation assay, chromatin immunoprecipitation, primary cortical cultures, EEG","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP demonstrating REST binding to Gad1, combined with cellular assays in KO model","pmids":["31294445"],"is_preprint":false},{"year":2009,"finding":"In the Cln5-/- mouse, neuron loss begins in the cortex and only subsequently occurs in thalamic relay nuclei, in marked contrast to other NCL models where neuron loss begins in the thalamus; this is preceded by early and localized glial responses in the thalamocortical system.","method":"Stereological analysis, immunohistochemistry, quantitative cell counting across disease progression stages","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 — systematic stereological analysis defining pathway position and sequence of neurodegeneration, 37 citations","pmids":["19385065"],"is_preprint":false}],"current_model":"CLN5 encodes a soluble lysosomal glycoprotein that functions as the BMP (bis(monoacylglycero)phosphate) synthase, catalyzing BMP biosynthesis via an energy-independent base exchange reaction between two LPG molecules; it also has cysteine palmitoyl thioesterase (S-depalmitoylase) activity mediated by a catalytic triad (Cys280-His166-Glu183); CLN5 is processed from a type II transmembrane precursor by SPPL3 into a mature soluble form anchored to the lysosomal lumen via an amphipathic helix; it interacts with multiple NCL proteins (CLN1-3, CLN6, CLN8) and regulates endolysosomal trafficking by functioning in a complex with CLN3 to control RAB7A-dependent retromer recruitment, endolysosome fusion, and lysosomal sorting receptor stability; CLN5 protein levels are controlled by KCTD7-mediated CUL3 ubiquitin ligase-dependent proteasomal degradation."},"narrative":{"teleology":[{"year":1998,"claim":"Positional cloning established CLN5 as a novel disease gene, answering the molecular basis of Finnish variant late infantile neuronal ceroid lipofuscinosis and enabling all subsequent functional studies.","evidence":"Linkage analysis and mutation sequencing in Finnish vLINCL families identified three causative mutations","pmids":["9662406"],"confidence":"High","gaps":["No protein characterization or subcellular localization","Function of the gene product entirely unknown","Original transmembrane topology prediction was later revised"]},{"year":2002,"claim":"Biochemical and localization studies overturned the initial transmembrane protein prediction, establishing CLN5 as a soluble lysosomal glycoprotein that physically interacts with CLN2 and CLN3, placing it within the NCL protein network.","evidence":"Confocal microscopy, deglycosylation, and reciprocal co-immunoprecipitation plus in vitro binding assays in BHK-21 and COS-1 cells","pmids":["11971870","12134079"],"confidence":"High","gaps":["Enzymatic function unknown","Molecular basis for interactions with CLN2/CLN3 undefined","Contribution of different initiator methionines to function unclear"]},{"year":2004,"claim":"The Cln5 knockout mouse recapitulated human disease features—storage material accumulation, cortical neurodegeneration, and vision loss—providing a functional model and demonstrating that CLN5 is essential for neuronal survival in defined brain regions.","evidence":"Targeted exon 3 deletion in mice; electron microscopy, immunohistochemistry, and transcript profiling","pmids":["15459177","15207259"],"confidence":"High","gaps":["Biochemical substrate or enzymatic activity of CLN5 still unknown","Mechanism linking CLN5 loss to storage material accumulation undefined","Why certain neuron populations are selectively vulnerable unclear"]},{"year":2009,"claim":"Expanding the NCL interactome, CLN5 was shown to interact with CLN1/PPT1, CLN6, and CLN8, and the distinctive cortex-first pattern of neurodegeneration in Cln5−/− mice was delineated, distinguishing CLN5 disease pathology from other NCL subtypes.","evidence":"Co-immunoprecipitation for interaction network; stereological analysis of neurodegeneration across disease stages in Cln5−/− mice","pmids":["19941651","19385065"],"confidence":"Medium","gaps":["Functional significance of each NCL protein interaction not resolved","Whether interactions are direct or within larger complexes not determined for all partners","Molecular link between CLN5 and neurodegeneration pattern unknown"]},{"year":2012,"claim":"CLN5 was positioned as a regulator of endosomal sorting: its depletion reduced GTP-Rab7 and caused degradation of lysosomal sorting receptors sortilin and CI-MPR through defective retromer recruitment, providing the first mechanistic link between CLN5 and membrane trafficking.","evidence":"siRNA knockdown in HeLa cells with co-immunoprecipitation, Rab7 activation assay, and retromer recruitment analysis","pmids":["22431521"],"confidence":"High","gaps":["Whether CLN5 acts directly on Rab7 or via an intermediary unknown","How CLN5 enzymatic activity relates to retromer function not established","Lipid perturbations in CLN5-deficient cells observed but not explained mechanistically"]},{"year":2013,"claim":"The biosynthetic processing of CLN5 was resolved: it is synthesized as a type II transmembrane protein whose N-terminal and TM domains are removed, yielding a soluble luminal protein anchored by an amphipathic helix; all eight N-glycosylation sites are utilized with differential roles in folding versus lysosomal targeting.","evidence":"Systematic mutagenesis of glycosylation sites and topology mapping with protease protection in transfected cells","pmids":["24038957","24058541"],"confidence":"High","gaps":["Identity of the protease generating the mature form not yet established","Whether amphipathic helix mediates membrane interactions relevant to enzymatic function unknown"]},{"year":2017,"claim":"Two key advances: SPPL3 was identified as the intramembrane protease cleaving CLN5's transmembrane precursor to generate the mature soluble form, and the first enzymatic activity—glycoside hydrolase activity—was demonstrated for both Dictyostelium and human CLN5.","evidence":"SPPL family overexpression/inhibitor studies; glycoside hydrolase assay with purified protein and mass spectrometry-based interactomics","pmids":["28442266","29128403"],"confidence":"Medium","gaps":["Physiological glycoside hydrolase substrates not identified","Whether glycoside hydrolase activity is the primary function in mammalian lysosomes unknown","SPPL3 cleavage not yet demonstrated with endogenous expression levels"]},{"year":2021,"claim":"CLN5 and CLN3 were shown to form a functional endolysosomal complex that controls RAB7A interactions with effectors and endolysosome fusion, directly linking CLN5 to the autophagy–lysosomal degradation axis and explaining trafficking defects in disease.","evidence":"CRISPR knockout, co-immunoprecipitation, endosome fusion assays, and CRISPRi in iPSC-derived neurons","pmids":["34060589","34680045"],"confidence":"High","gaps":["Stoichiometry and structure of CLN3–CLN5 complex unknown","Whether enzymatic activity of CLN5 is required for complex function not tested","Relative contributions of BMP synthesis versus trafficking roles to disease pathology unclear"]},{"year":2022,"claim":"The crystal structure revealed CLN5 as an NlpC/P60 superfamily thioesterase with S-depalmitoylase activity via a Cys280-His166 catalytic dyad, and independently, CLN5 was identified as a substrate of the CRL3-KCTD7 ubiquitin ligase whose turnover controls ER-to-Golgi trafficking of lysosomal enzymes via CLN6/CLN8.","evidence":"X-ray crystallography and fluorescent thioesterase assay with active-site mutagenesis; ubiquitination assays and KCTD7 knockout cell analysis","pmids":["35427157","35921411"],"confidence":"High","gaps":["Physiological depalmitoylation substrates not identified","Whether thioesterase and BMP synthase activities use the same active site not resolved","Structural basis of KCTD7-CLN5 recognition unknown"]},{"year":2023,"claim":"CLN5 was definitively identified as the lysosomal BMP synthase, resolving a decades-long search for this enzyme: it catalyzes BMP synthesis via energy-independent transacylation between two LPG molecules, and its loss causes massive LPG accumulation with BMP depletion.","evidence":"Lipidomics of CLN5 knockout cells and in vitro enzymatic reconstitution with purified protein","pmids":["37708259"],"confidence":"High","gaps":["How BMP synthesis deficiency leads to the storage material accumulation and neurodegeneration not mechanistically defined","Whether BMP synthase and thioesterase activities are independent or share a catalytic mechanism unresolved","Regulation of BMP synthase activity in vivo poorly understood"]},{"year":null,"claim":"Key open questions include: the relationship between CLN5's dual enzymatic activities (BMP synthase and thioesterase), identification of physiological depalmitoylation substrates, and how loss of BMP synthesis drives the selective neuronal vulnerability characteristic of CLN5 disease.","evidence":"","pmids":[],"confidence":"Low","gaps":["No study has tested whether the same catalytic site mediates both BMP synthesis and depalmitoylation","Endogenous thioesterase substrates remain unidentified","Mechanism linking BMP depletion to storage material formation and neurodegeneration not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[9,12,14]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[12,15]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[14]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[14]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[1,5,6,14,16,20]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[6,13]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[4,11]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[9]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[4,11,16]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[14,17]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[11,18]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,21]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[13]}],"complexes":["CLN3-CLN5 endolysosomal complex","CRL3-KCTD7 (as substrate)"],"partners":["CLN3","CLN2","CLN1","CLN6","CLN8","KCTD7","SPPL3","SORT1"],"other_free_text":[]},"mechanistic_narrative":"CLN5 is a soluble lysosomal glycoprotein that functions as the BMP (bis(monoacylglycero)phosphate) synthase, catalyzing an energy-independent base exchange reaction between two lysophosphatidylglycerol molecules, and additionally possesses cysteine palmitoyl thioesterase (S-depalmitoylase) activity mediated by a Cys280-His166-Glu183 catalytic triad within an NlpC/P60 superfamily fold [PMID:37708259, PMID:35427157]. Synthesized as a type II transmembrane precursor, CLN5 is cleaved by the intramembrane protease SPPL3 to yield a mature soluble form (residues 93–407) that is retained in the lysosomal lumen via an amphipathic helix and trafficked through both mannose-6-phosphate receptor-dependent and -independent pathways [PMID:28442266, PMID:24038957, PMID:20052765]. CLN5 forms an endolysosomal complex with CLN3 that controls RAB7A-dependent retromer recruitment, endolysosome fusion, and stability of the sorting receptors sortilin and CI-MPR; its protein levels are regulated by KCTD7–CUL3 ubiquitin ligase-mediated proteasomal degradation, and excess CLN5 disrupts CLN6/CLN8-dependent ER-to-Golgi trafficking of lysosomal enzymes [PMID:34060589, PMID:22431521, PMID:35921411]. Loss-of-function mutations in CLN5 cause Finnish variant late infantile neuronal ceroid lipofuscinosis (vLINCL), characterized by accumulation of autofluorescent storage material and progressive cortical neurodegeneration [PMID:9662406, PMID:15459177]."},"prefetch_data":{"uniprot":{"accession":"O75503","full_name":"Bis(monoacylglycero)phosphate synthase CLN5","aliases":["Ceroid-lipofuscinosis neuronal protein 5","Protein CLN5","Palmitoyl protein thioesterase CLN5","S-depalmitoylase CLN5"],"length_aa":358,"mass_kda":41.5,"function":"Catalyzes the synthesis of bis(monoacylglycero)phosphate (BMP) via transacylation of 2 molecules of lysophosphatidylglycerol (LPG) (PubMed:37708259). BMP also known as lysobisphosphatidic acid plays a key role in the formation of intraluminal vesicles and in maintaining intracellular cholesterol homeostasis (PubMed:37708259). Can use only LPG as the exclusive lysophospholipid acyl donor for base exchange and displays BMP synthase activity towards various LPGs (LPG 14:0, LPG 16:0, LPG 18:0, LPG 18:1) with a higher preference for longer chain lengths (PubMed:37708259). Plays a role in influencing the retrograde trafficking of lysosomal sorting receptors SORT1 and IGF2R from the endosomes to the trans-Golgi network by controlling the recruitment of retromer complex to the endosomal membrane (PubMed:22431521). Regulates the localization and activation of RAB7A which is required to recruit the retromer complex to the endosomal membrane (PubMed:22431521) Exhibits palmitoyl protein thioesterase (S-depalmitoylation) activity in vitro and most likely plays a role in protein S-depalmitoylation","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/O75503/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CLN5","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CLN5","total_profiled":1310},"omim":[{"mim_id":"609055","title":"CEROID LIPOFUSCINOSIS, NEURONAL, 9; CLN9","url":"https://www.omim.org/entry/609055"},{"mim_id":"608102","title":"CLN5 INTRACELLULAR TRAFFICKING PROTEIN; CLN5","url":"https://www.omim.org/entry/608102"},{"mim_id":"607998","title":"TRIPEPTIDYL PEPTIDASE I; TPP1","url":"https://www.omim.org/entry/607998"},{"mim_id":"607042","title":"CLN3 LYSOSOMAL/ENDOSOMAL TRANSMEMBRANE PROTEIN, BATTENIN; CLN3","url":"https://www.omim.org/entry/607042"},{"mim_id":"602543","title":"BASIC TRANSCRIPTION FACTOR 3 PSEUDOGENE 11; BTF3P11","url":"https://www.omim.org/entry/602543"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CLN5"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O75503","domains":[{"cath_id":"-","chopping":"65-346","consensus_level":"medium","plddt":89.8236,"start":65,"end":346}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O75503","model_url":"https://alphafold.ebi.ac.uk/files/AF-O75503-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O75503-F1-predicted_aligned_error_v6.png","plddt_mean":82.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CLN5","jax_strain_url":"https://www.jax.org/strain/search?query=CLN5"},"sequence":{"accession":"O75503","fasta_url":"https://rest.uniprot.org/uniprotkb/O75503.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O75503/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O75503"}},"corpus_meta":[{"pmid":"19174516","id":"PMC_19174516","title":"VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19174516","citation_count":543,"is_preprint":false},{"pmid":"9662406","id":"PMC_9662406","title":"CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9662406","citation_count":224,"is_preprint":false},{"pmid":"11971870","id":"PMC_11971870","title":"Lysosomal localization of the neuronal ceroid lipofuscinosis CLN5 protein.","date":"2002","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11971870","citation_count":100,"is_preprint":false},{"pmid":"12134079","id":"PMC_12134079","title":"Neuronal ceroid lipofuscinoses are connected at molecular level: interaction of CLN5 protein with CLN2 and CLN3.","date":"2002","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/12134079","citation_count":90,"is_preprint":false},{"pmid":"16033706","id":"PMC_16033706","title":"A mutation in canine CLN5 causes neuronal ceroid lipofuscinosis in Border collie dogs.","date":"2005","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/16033706","citation_count":74,"is_preprint":false},{"pmid":"15459177","id":"PMC_15459177","title":"A mouse model for Finnish variant late infantile neuronal ceroid lipofuscinosis, CLN5, reveals neuropathology associated with early aging.","date":"2004","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15459177","citation_count":71,"is_preprint":false},{"pmid":"22431521","id":"PMC_22431521","title":"The role of ceroid lipofuscinosis neuronal protein 5 (CLN5) in endosomal sorting.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22431521","citation_count":67,"is_preprint":false},{"pmid":"19941651","id":"PMC_19941651","title":"Novel interactions of CLN5 support molecular networking between Neuronal Ceroid Lipofuscinosis proteins.","date":"2009","source":"BMC cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19941651","citation_count":67,"is_preprint":false},{"pmid":"10953198","id":"PMC_10953198","title":"Phenotype-genotype correlation in eight patients with Finnish variant late infantile NCL (CLN5).","date":"2000","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10953198","citation_count":62,"is_preprint":false},{"pmid":"20157158","id":"PMC_20157158","title":"CLN5 mutations are frequent in juvenile and late-onset non-Finnish patients with NCL.","date":"2010","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20157158","citation_count":59,"is_preprint":false},{"pmid":"8644710","id":"PMC_8644710","title":"The age of human mutation: genealogical and linkage disequilibrium analysis of the CLN5 mutation in the Finnish population.","date":"1996","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8644710","citation_count":59,"is_preprint":false},{"pmid":"17988881","id":"PMC_17988881","title":"A new large animal model of CLN5 neuronal ceroid lipofuscinosis in Borderdale sheep is caused by a nucleotide substitution at a consensus splice site (c.571+1G>A) leading to excision of exon 3.","date":"2007","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/17988881","citation_count":58,"is_preprint":false},{"pmid":"37708259","id":"PMC_37708259","title":"The Batten disease gene product CLN5 is the lysosomal bis(monoacylglycero)phosphate synthase.","date":"2023","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37708259","citation_count":55,"is_preprint":false},{"pmid":"30078766","id":"PMC_30078766","title":"Longitudinal In Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease.","date":"2018","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30078766","citation_count":54,"is_preprint":false},{"pmid":"15207259","id":"PMC_15207259","title":"The mouse ortholog of the neuronal ceroid lipofuscinosis CLN5 gene encodes a soluble lysosomal glycoprotein expressed in the developing brain.","date":"2004","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/15207259","citation_count":53,"is_preprint":false},{"pmid":"24058541","id":"PMC_24058541","title":"The role of N-glycosylation in folding, trafficking, and functionality of lysosomal protein CLN5.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24058541","citation_count":51,"is_preprint":false},{"pmid":"28487519","id":"PMC_28487519","title":"Retinal Degeneration In A Mouse Model Of CLN5 Disease Is Associated With Compromised Autophagy.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28487519","citation_count":50,"is_preprint":false},{"pmid":"10477428","id":"PMC_10477428","title":"Molecular basis of the neuronal ceroid lipofuscinoses: mutations in CLN1, CLN2, CLN3, and CLN5.","date":"1999","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/10477428","citation_count":49,"is_preprint":false},{"pmid":"29128403","id":"PMC_29128403","title":"Cln5 is secreted and functions as a glycoside hydrolase in Dictyostelium.","date":"2017","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/29128403","citation_count":45,"is_preprint":false},{"pmid":"23160995","id":"PMC_23160995","title":"CLN5 and CLN8 protein association with ceramide synthase: biochemical and proteomic approaches.","date":"2012","source":"Electrophoresis","url":"https://pubmed.ncbi.nlm.nih.gov/23160995","citation_count":45,"is_preprint":false},{"pmid":"8661106","id":"PMC_8661106","title":"Efficient construction of a physical map by fiber-FISH of the CLN5 region: refined assignment and long-range contig covering the critical region on 13q22.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8661106","citation_count":44,"is_preprint":false},{"pmid":"22182690","id":"PMC_22182690","title":"Cln5-deficiency in mice leads to microglial activation, defective myelination and changes in lipid metabolism.","date":"2011","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/22182690","citation_count":43,"is_preprint":false},{"pmid":"25934231","id":"PMC_25934231","title":"Golden Retriever dogs with neuronal ceroid lipofuscinosis have a two-base-pair deletion and frameshift in CLN5.","date":"2015","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25934231","citation_count":41,"is_preprint":false},{"pmid":"15728307","id":"PMC_15728307","title":"A CLN5 mutation causing an atypical neuronal ceroid lipofuscinosis of juvenile onset.","date":"2005","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15728307","citation_count":41,"is_preprint":false},{"pmid":"19309691","id":"PMC_19309691","title":"Retention of lysosomal protein CLN5 in the endoplasmic reticulum causes neuronal ceroid lipofuscinosis in Asian sibship.","date":"2009","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/19309691","citation_count":40,"is_preprint":false},{"pmid":"30037983","id":"PMC_30037983","title":"An Alzheimer's Disease-Linked Loss-of-Function CLN5 Variant Impairs Cathepsin D Maturation, Consistent with a Retromer Trafficking Defect.","date":"2018","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30037983","citation_count":39,"is_preprint":false},{"pmid":"20052765","id":"PMC_20052765","title":"The neuronal ceroid lipofuscinosis protein CLN5: new insights into cellular maturation, transport, and consequences of mutations.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20052765","citation_count":37,"is_preprint":false},{"pmid":"19385065","id":"PMC_19385065","title":"Progressive thalamocortical neuron loss in Cln5 deficient mice: Distinct effects in Finnish variant late infantile NCL.","date":"2009","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/19385065","citation_count":37,"is_preprint":false},{"pmid":"27203721","id":"PMC_27203721","title":"Australian Cattle Dogs with Neuronal Ceroid Lipofuscinosis are Homozygous for a CLN5 Nonsense Mutation Previously Identified in Border Collies.","date":"2016","source":"Journal of veterinary internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27203721","citation_count":35,"is_preprint":false},{"pmid":"17607606","id":"PMC_17607606","title":"Revelation of a novel CLN5 mutation in early juvenile neuronal ceroid lipofuscinosis.","date":"2007","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/17607606","citation_count":35,"is_preprint":false},{"pmid":"24269732","id":"PMC_24269732","title":"Inhibition of storage pathology in prenatal CLN5-deficient sheep neural cultures by lentiviral gene therapy.","date":"2013","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/24269732","citation_count":34,"is_preprint":false},{"pmid":"30655561","id":"PMC_30655561","title":"Autophagy-lysosome pathway alterations and alpha-synuclein up-regulation in the subtype of neuronal ceroid lipofuscinosis, CLN5 disease.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30655561","citation_count":33,"is_preprint":false},{"pmid":"25359263","id":"PMC_25359263","title":"Adult-onset autosomal recessive ataxia associated with neuronal ceroid lipofuscinosis type 5 gene (CLN5) mutations.","date":"2014","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25359263","citation_count":31,"is_preprint":false},{"pmid":"32257390","id":"PMC_32257390","title":"Proteomic and functional analyses in disease models reveal CLN5 protein involvement in mitochondrial dysfunction.","date":"2020","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/32257390","citation_count":28,"is_preprint":false},{"pmid":"16935476","id":"PMC_16935476","title":"Neuronal ceroid lipofuscinosis in Devon cattle is caused by a single base duplication (c.662dupG) in the bovine CLN5 gene.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16935476","citation_count":28,"is_preprint":false},{"pmid":"16814585","id":"PMC_16814585","title":"Two novel CLN5 mutations in a Portuguese patient with vLINCL: insights into molecular mechanisms of CLN5 deficiency.","date":"2006","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16814585","citation_count":28,"is_preprint":false},{"pmid":"26664787","id":"PMC_26664787","title":"Molecular neuropathology of the synapse in sheep with CLN5 Batten disease.","date":"2015","source":"Brain and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/26664787","citation_count":27,"is_preprint":false},{"pmid":"28468312","id":"PMC_28468312","title":"Induced Pluripotent Stem Cells Derived from a CLN5 Patient Manifest Phenotypic Characteristics of Neuronal Ceroid Lipofuscinoses.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28468312","citation_count":27,"is_preprint":false},{"pmid":"10992246","id":"PMC_10992246","title":"CLN-1 and CLN-5, genes for infantile and variant late infantile neuronal ceroid lipofuscinoses, are expressed in the embryonic human brain.","date":"2000","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10992246","citation_count":27,"is_preprint":false},{"pmid":"33930398","id":"PMC_33930398","title":"Intravitreal gene therapy protects against retinal dysfunction and degeneration in sheep with CLN5 Batten disease.","date":"2021","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/33930398","citation_count":26,"is_preprint":false},{"pmid":"28065762","id":"PMC_28065762","title":"Characterisation of early changes in ovine CLN5 and CLN6 Batten disease neural cultures for the rapid screening of therapeutics.","date":"2017","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/28065762","citation_count":26,"is_preprint":false},{"pmid":"30048658","id":"PMC_30048658","title":"Secretion and function of Cln5 during the early stages of Dictyostelium development.","date":"2018","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/30048658","citation_count":25,"is_preprint":false},{"pmid":"28442266","id":"PMC_28442266","title":"CLN5 is cleaved by members of the SPP/SPPL family to produce a mature soluble protein.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/28442266","citation_count":25,"is_preprint":false},{"pmid":"34060589","id":"PMC_34060589","title":"CLN5 and CLN3 function as a complex to regulate endolysosome function.","date":"2021","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/34060589","citation_count":25,"is_preprint":false},{"pmid":"35427157","id":"PMC_35427157","title":"Cln5 represents a new type of cysteine-based S-depalmitoylase linked to neurodegeneration.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35427157","citation_count":24,"is_preprint":false},{"pmid":"33792748","id":"PMC_33792748","title":"A lysosomal enigma CLN5 and its significance in understanding neuronal ceroid lipofuscinosis.","date":"2021","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/33792748","citation_count":23,"is_preprint":false},{"pmid":"27488642","id":"PMC_27488642","title":"An EEG Investigation of Sleep Homeostasis in Healthy and CLN5 Batten Disease Affected Sheep.","date":"2016","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27488642","citation_count":23,"is_preprint":false},{"pmid":"35921411","id":"PMC_35921411","title":"KCTD7 mutations impair the trafficking of lysosomal enzymes through CLN5 accumulation to cause neuronal ceroid lipofuscinoses.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35921411","citation_count":22,"is_preprint":false},{"pmid":"34680045","id":"PMC_34680045","title":"Deficiency of the Lysosomal Protein CLN5 Alters Lysosomal Function and Movement.","date":"2021","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/34680045","citation_count":20,"is_preprint":false},{"pmid":"25303899","id":"PMC_25303899","title":"Neuronal ceroid lipofuscinosis genes, CLN2, CLN3 and CLN5 are spatially and temporally co-expressed in a developing mouse brain.","date":"2014","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25303899","citation_count":19,"is_preprint":false},{"pmid":"26342652","id":"PMC_26342652","title":"Proteolytic processing of the neuronal ceroid lipofuscinosis related lysosomal protein CLN5.","date":"2015","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/26342652","citation_count":18,"is_preprint":false},{"pmid":"28733362","id":"PMC_28733362","title":"Loss of Cln5 causes altered neurogenesis in a mouse model of a childhood neurodegenerative disorder.","date":"2017","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/28733362","citation_count":17,"is_preprint":false},{"pmid":"24038957","id":"PMC_24038957","title":"Topology and membrane anchoring of the lysosomal storage disease-related protein CLN5.","date":"2013","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/24038957","citation_count":16,"is_preprint":false},{"pmid":"34291044","id":"PMC_34291044","title":"Aberrant Autophagy Impacts Growth and Multicellular Development in a Dictyostelium Knockout Model of CLN5 Disease.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34291044","citation_count":16,"is_preprint":false},{"pmid":"32087303","id":"PMC_32087303","title":"Mfsd8 localizes to endocytic compartments and influences the secretion of Cln5 and cathepsin D in Dictyostelium.","date":"2020","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/32087303","citation_count":16,"is_preprint":false},{"pmid":"11332769","id":"PMC_11332769","title":"Studies of homogenous populations: CLN5 and CLN8.","date":"2001","source":"Advances in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11332769","citation_count":15,"is_preprint":false},{"pmid":"31294445","id":"PMC_31294445","title":"Loss of Cln5 leads to altered Gad1 expression and deficits in interneuron development in mice.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31294445","citation_count":14,"is_preprint":false},{"pmid":"31101435","id":"PMC_31101435","title":"A mixed breed dog with neuronal ceroid lipofuscinosis is homozygous for a CLN5 nonsense mutation previously identified in Border Collies and Australian Cattle Dogs.","date":"2019","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31101435","citation_count":14,"is_preprint":false},{"pmid":"35681535","id":"PMC_35681535","title":"Lysosomal Proteomics Links Disturbances in Lipid Homeostasis and Sphingolipid Metabolism to CLN5 Disease.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35681535","citation_count":13,"is_preprint":false},{"pmid":"10419622","id":"PMC_10419622","title":"Prenatal diagnosis of variant late infantile neuronal ceroid lipofuscinosis (vLINCL[Finnish]; CLN5).","date":"1999","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/10419622","citation_count":13,"is_preprint":false},{"pmid":"8020979","id":"PMC_8020979","title":"A variant form of late infantile neuronal ceroid lipofuscinosis (CLN5) is not an allelic form of Batten (Spielmeyer-Vogt-Sjögren, CLN3) disease: exclusion of linkage to the CLN3 region of chromosome 16.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8020979","citation_count":11,"is_preprint":false},{"pmid":"36368077","id":"PMC_36368077","title":"Lysosomal dysfunction, autophagic defects, and CLN5 accumulation underlie the pathogenesis of KCTD7-mutated neuronal ceroid lipofuscinoses.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/36368077","citation_count":9,"is_preprint":false},{"pmid":"38272448","id":"PMC_38272448","title":"Mechanisms regulating the intracellular trafficking and release of CLN5 and CTSD.","date":"2024","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/38272448","citation_count":8,"is_preprint":false},{"pmid":"33507209","id":"PMC_33507209","title":"Association of the Recurrent Rare Variant c.415T>C p.Phe139Leu in CLN5 With a Recessively Inherited Macular Dystrophy.","date":"2021","source":"JAMA ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/33507209","citation_count":8,"is_preprint":false},{"pmid":"32302805","id":"PMC_32302805","title":"Novel likely disease-causing CLN5 variants identified in Pakistani patients with neuronal ceroid lipofuscinosis.","date":"2020","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32302805","citation_count":8,"is_preprint":false},{"pmid":"37942487","id":"PMC_37942487","title":"Efficacy of dual intracerebroventricular and intravitreal CLN5 gene therapy in sheep prompts the first clinical trial to treat CLN5 Batten disease.","date":"2023","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37942487","citation_count":8,"is_preprint":false},{"pmid":"37614821","id":"PMC_37614821","title":"Long-term safety and dose escalation of intracerebroventricular CLN5 gene therapy in sheep supports clinical translation for CLN5 Batten disease.","date":"2023","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37614821","citation_count":8,"is_preprint":false},{"pmid":"37246363","id":"PMC_37246363","title":"Characterization of neuropathology in ovine CLN5 and CLN6 neuronal ceroid lipofuscinoses (Batten disease).","date":"2023","source":"Developmental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/37246363","citation_count":7,"is_preprint":false},{"pmid":"34141843","id":"PMC_34141843","title":"Electroretinography data from ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinoses.","date":"2021","source":"Data in brief","url":"https://pubmed.ncbi.nlm.nih.gov/34141843","citation_count":7,"is_preprint":false},{"pmid":"32983231","id":"PMC_32983231","title":"Functional Analysis of a Novel CLN5 Mutation Identified in a Patient With Neuronal Ceroid Lipofuscinosis.","date":"2020","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32983231","citation_count":7,"is_preprint":false},{"pmid":"36632184","id":"PMC_36632184","title":"Progressive MRI brain volume changes in ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinosis.","date":"2023","source":"Brain communications","url":"https://pubmed.ncbi.nlm.nih.gov/36632184","citation_count":7,"is_preprint":false},{"pmid":"10191122","id":"PMC_10191122","title":"Positional cloning of the CLN5 gene defective in the Finnish variant of the LINCL.","date":"1999","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10191122","citation_count":7,"is_preprint":false},{"pmid":"30264640","id":"PMC_30264640","title":"Novel Mutations in CLN5 of Chinese Patients With Neuronal Ceroid Lipofuscinosis.","date":"2018","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30264640","citation_count":6,"is_preprint":false},{"pmid":"36347825","id":"PMC_36347825","title":"HAGLROS knockdown restrained cell proliferation, migration and invasion and facilitated apoptosis in laryngeal cancer via miR-138-5p/CLN5 axis.","date":"2022","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/36347825","citation_count":6,"is_preprint":false},{"pmid":"38055807","id":"PMC_38055807","title":"Mechanistic Insights into S-Depalmitolyse Activity of Cln5 Protein Linked to Neurodegeneration and Batten Disease: A QM/MM Study.","date":"2023","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/38055807","citation_count":5,"is_preprint":false},{"pmid":"33777210","id":"PMC_33777210","title":"Knockdown of CLN5 inhibits the tumorigenic properties of glioblastoma cells via the Akt/mTOR signaling pathway.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33777210","citation_count":5,"is_preprint":false},{"pmid":"32487141","id":"PMC_32487141","title":"CLN5 in heterozygosis may protect against the development of tumors in a VHL patient.","date":"2020","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32487141","citation_count":5,"is_preprint":false},{"pmid":"30919163","id":"PMC_30919163","title":"The Neuronal Ceroid Lipofuscinoses-Linked Loss of Function CLN5 and CLN8 Variants Disrupt Normal Lysosomal Function.","date":"2019","source":"Neuromolecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30919163","citation_count":4,"is_preprint":false},{"pmid":"22532218","id":"PMC_22532218","title":"[Neuronal ceroid lipofuscinosis: diagnostic algorithm and clinical description of the Finnish (CLN5) and Turkish (CLN7) variants late infantile].","date":"2012","source":"Revista de neurologia","url":"https://pubmed.ncbi.nlm.nih.gov/22532218","citation_count":4,"is_preprint":false},{"pmid":"10480355","id":"PMC_10480355","title":"Transcript identification on the CLN5 region on chromosome 13q22.","date":"1999","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10480355","citation_count":3,"is_preprint":false},{"pmid":"40346285","id":"PMC_40346285","title":"CLN5 deficiency impairs glucose uptake and uncovers PHGDH as a potential biomarker in Batten disease.","date":"2025","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/40346285","citation_count":2,"is_preprint":false},{"pmid":"36437924","id":"PMC_36437924","title":"An altered transcriptome underlies cln5-deficiency phenotypes in Dictyostelium discoideum.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36437924","citation_count":2,"is_preprint":false},{"pmid":"38141358","id":"PMC_38141358","title":"Characterization of two human induced pluripotent stem cell lines derived from Batten disease patient fibroblasts harbouring CLN5 mutations.","date":"2023","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/38141358","citation_count":2,"is_preprint":false},{"pmid":"34678132","id":"PMC_34678132","title":"A novel CLN5 mutation in Turkish patient with variant late-onset neuronal ceroid lipofuscinosis and recurrent fractures that causes severe morbidity.","date":"2021","source":"Neurocase","url":"https://pubmed.ncbi.nlm.nih.gov/34678132","citation_count":1,"is_preprint":false},{"pmid":"40181626","id":"PMC_40181626","title":"Magnetic Resonance Imaging as a Readout of CLN5 Gene Therapy Efficacy in Sheep.","date":"2025","source":"Brain and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/40181626","citation_count":1,"is_preprint":false},{"pmid":"39667065","id":"PMC_39667065","title":"Drug-refractory epilepsy due to a novel CLN5 mutation: A report of three patients from an Indian family.","date":"2024","source":"Seizure","url":"https://pubmed.ncbi.nlm.nih.gov/39667065","citation_count":1,"is_preprint":false},{"pmid":"41457644","id":"PMC_41457644","title":"Brain-Directed AAV Gene Therapy Rescues a Mouse Model of the CLN5 Form of Neuronal Ceroid Lipofuscinosis Disease and Normalizes a Blood Plasma Biomarker of Neurodegeneration.","date":"2026","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/41457644","citation_count":0,"is_preprint":false},{"pmid":"42031177","id":"PMC_42031177","title":"CLN5 disease-causing mutations impact lysosomal biology by affecting intracellular degradation and protein trafficking.","date":"2026","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/42031177","citation_count":0,"is_preprint":false},{"pmid":"41003830","id":"PMC_41003830","title":"Genomic insights into autosomal recessive epilepsy: novel pathogenic variants in ITPA and CLN5 identified in consanguineous families.","date":"2025","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/41003830","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.02.13.638174","title":"Robust analytical methods for bis(monoacylglycero)phosphate profiling in health and disease","date":"2025-02-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.13.638174","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.02.630719","title":"CLN5 deficiency impairs glucose uptake in Batten disease","date":"2025-01-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.02.630719","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.05.28.596187","title":"The endolysosomal phospholipid bis(monoacylglycero)phosphate is synthesized via intra- and extracellular pathways","date":"2024-05-31","source":"bioRxiv","url":"https://doi.org/10.1101/2024.05.28.596187","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43700,"output_tokens":5796,"usd":0.10902},"stage2":{"model":"claude-opus-4-6","input_tokens":9382,"output_tokens":3256,"usd":0.192465},"total_usd":0.301485,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"CLN5 was identified as a novel gene encoding a putative transmembrane protein underlying Finnish variant late infantile neuronal ceroid lipofuscinosis (vLINCL), with three disease-causing mutations (one deletion, one nonsense, one missense) identified by positional cloning and sequence analysis.\",\n      \"method\": \"Positional cloning, linkage analysis, mutation sequencing\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original positional cloning with multiple mutations identified, foundational paper with 224 citations\",\n      \"pmids\": [\"9662406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CLN5 protein localizes predominantly to lysosomes and is a soluble lysosomal glycoprotein (~60 kDa, reduced to ~40 kDa by deglycosylation), not an integral transmembrane protein as originally predicted; the most common human vLINCL mutation blocks lysosomal targeting.\",\n      \"method\": \"Confocal immunofluorescence microscopy, immunoprecipitation, deglycosylation assays, transient transfection in BHK-21 cells\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical and imaging methods in single study, 100 citations\",\n      \"pmids\": [\"11971870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CLN5 protein directly interacts with CLN2 and CLN3 proteins; CLN5 is synthesized as four precursor forms due to alternative initiator methionines, all targeted to lysosomes, with the longest membrane-associated form mediating interactions with CLN2 and CLN3; disease mutations in CLN5 abolished interaction with CLN2 but not CLN3.\",\n      \"method\": \"Coimmunoprecipitation, in vitro binding assays, western blotting\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal Co-IP plus in vitro binding, multiple isoforms characterized, 90 citations\",\n      \"pmids\": [\"12134079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CLN5 interacts with multiple NCL proteins (CLN1/PPT1, CLN2/TPP1, CLN3, CLN6, CLN8); overexpression of PPT1 can facilitate lysosomal transport of mutated CLN5 normally retained in ER/Golgi; CLN5 also binds F1-ATPase, a known PPT1 binding partner.\",\n      \"method\": \"Coimmunoprecipitation, confocal microscopy, overexpression studies\",\n      \"journal\": \"BMC cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple Co-IP interactions confirmed, functional rescue experiment with PPT1 overexpression\",\n      \"pmids\": [\"19941651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CLN5 interacts with the lysosomal sorting receptor sortilin; CLN5 depletion causes degradation of lysosomal sorting receptors sortilin and CI-MPR due to defective retromer recruitment at endosomes, linked to reduced active (GTP-loaded) Rab7 levels.\",\n      \"method\": \"Coimmunoprecipitation, siRNA knockdown in HeLa cells, western blotting, immunofluorescence\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, KD with defined molecular phenotype, multiple orthogonal methods, 67 citations\",\n      \"pmids\": [\"22431521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"All eight N-glycosylation sites of CLN5 are utilized in vivo; glycosylation at N179, N252, N304, or N320 is required for proper protein folding (mutation causes ER retention), while N401 glycosylation is essential for lysosomal trafficking but not folding.\",\n      \"method\": \"Site-directed mutagenesis of individual Asn residues, localization studies by immunofluorescence, western blotting\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis of all 8 sites with functional readouts, 51 citations\",\n      \"pmids\": [\"24058541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CLN5 is synthesized as a type II transmembrane glycoprotein with cytoplasmic N-terminus, one TM segment, and a large luminal C-terminal domain containing an amphipathic helix (AH); cytoplasmic and TM domains are removed after signal peptide cleavage; the AH anchors mature CLN5 to the membrane lumen; CLN5 pathological mutants lacking AH are retained in the ER and degraded by the proteasome.\",\n      \"method\": \"Epitope-tagged CLN5 topology determination, protease protection assay, mutagenesis, immunofluorescence, proteasome inhibition\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic topology mapping with mutagenesis and functional consequences, 16 citations\",\n      \"pmids\": [\"24038957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CLN5 undergoes proteolytic C-terminal cleavage post-translationally in an acidic compartment, likely by a cysteine protease; two forms (~60 and ~56 kDa) are present in cells; processing occurs beyond the ER and can initiate from the trans-Golgi network.\",\n      \"method\": \"Cycloheximide chase analysis, pharmacological inhibition of proteases, transient transfection, western blotting\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological inhibitors used, kinetic pulse-chase, but no direct identification of the protease\",\n      \"pmids\": [\"26342652\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CLN5 is cleaved by SPPL3 (a member of the SPP/SPPL intramembrane protease family), generating a mature soluble protein consisting of residues 93-407; the remaining N-terminal fragment is then cleaved by SPPL3 and SPPL2b and degraded by the proteasome.\",\n      \"method\": \"Overexpression of SPPL family members, inhibitor studies, western blotting, immunofluorescence\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — specific protease identified with functional validation, 25 citations\",\n      \"pmids\": [\"28442266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Both Dictyostelium Cln5 and human CLN5 function as glycoside hydrolases, providing the first molecular enzymatic function attributed to CLN5; Dictyostelium Cln5 is secreted during growth and starvation; Cln5 immunoprecipitation identified 61 interacting proteins enriched for metabolic, catabolic, and hydrolytic functions including NCL-like proteins.\",\n      \"method\": \"Glycoside hydrolase enzymatic assay, immunoprecipitation coupled with mass spectrometry, localization by fluorescence microscopy, secretion assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzymatic assay demonstrated for both Dictyostelium and human CLN5, 45 citations\",\n      \"pmids\": [\"29128403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A CLN5 missense variant (p.Asn320Ser) linked to Alzheimer's disease causes glycosylation defects leading to ER retention of CLN5 and reduced delivery to endolysosomal compartment; this variant reduces normal cathepsin D processing and decreases full-length APP levels, consistent with a retromer trafficking defect.\",\n      \"method\": \"Expression of mutant protein, glycosylation analysis, immunofluorescence localization, western blotting for cathepsin D maturation and APP levels\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional readouts in a single study linking CLN5 mutation to retromer and cathepsin D processing\",\n      \"pmids\": [\"30037983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CLN5 and CLN3 function as an endolysosomal complex; CLN5 deletion causes retromer dysfunction and impaired endolysosome fusion, leading to delayed degradation of endocytic proteins and defective autophagy; CLN5 regulates CLN3 interactions with RAB7A and a subset of RAB7A effectors.\",\n      \"method\": \"CRISPR knockout, Co-IP, endosome fusion assays, western blotting, immunofluorescence\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods defining CLN5-CLN3 complex and downstream RAB7A pathway, 25 citations\",\n      \"pmids\": [\"34060589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CLN5 (Cln5) crystal structure was solved and revealed a region homologous to the catalytic domain of N1pC/P60 superfamily papain-like enzymes; CLN5 has cysteine palmitoyl thioesterase (S-depalmitoylation) activity; the catalytic residues histidine-166 and cysteine-280 are critical for this activity; CLN5-deficient neuronal progenitor cells showed reduced thioesterase activity.\",\n      \"method\": \"X-ray crystallography, fluorescent substrate thioesterase assay, active-site mutagenesis, cell-based thioesterase activity assay\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure, in vitro enzymatic assay, mutagenesis, and cellular functional validation in single study\",\n      \"pmids\": [\"35427157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The CRL3-KCTD7 E3 ubiquitin ligase complex ubiquitinates CLN5 targeting it for proteasomal degradation; NCL patient-derived KCTD7 mutations disrupt KCTD7-CLN5 interaction causing CLN5 accumulation in the ER; excess CLN5 disrupts CLN6/CLN8 interaction with lysosomal enzymes, impairing ER-to-Golgi trafficking of lysosomal enzymes.\",\n      \"method\": \"Co-IP, ubiquitination assays, KCTD7 knockout cells, western blotting, immunofluorescence\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ubiquitination assay plus Co-IP plus functional trafficking readout, mechanistically placing CLN5 as CRL3-KCTD7 substrate\",\n      \"pmids\": [\"35921411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CLN5 is the lysosomal BMP (bis(monoacylglycero)phosphate) synthase; CLN5-deficient cells show massive accumulation of the BMP synthesis precursor LPG and depletion of BMP species; CLN5 mediates BMP synthesis through an energy-independent base exchange reaction between two LPG molecules, with increased activity on BMP-laden vesicles.\",\n      \"method\": \"Lipidomics of CLN5 knockout cells, in vitro enzymatic reconstitution with purified protein, lipid mass spectrometry\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic reconstitution demonstrating BMP synthase activity, lipidomics validation in KO cells, 55 citations\",\n      \"pmids\": [\"37708259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"QM/MM computational analysis confirmed the catalytic triad Cys280-His166-Glu183 is critical for CLN5 S-depalmitoylation activity; the S-depalmitoylation step is rate-limiting with a barrier of ~26.1 kcal/mol; this study defined the atomic-level reaction mechanism.\",\n      \"method\": \"QM/MM molecular dynamics at ωB97X-D/6-31G(d,p):AMBER level, NBO charge analysis, local mode force constants\",\n      \"journal\": \"Journal of the American Chemical Society\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 4 (computational) — high-level QM/MM study confirming previously crystallographically and experimentally established catalytic residues\",\n      \"pmids\": [\"38055807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CLN5 is proteolytically cleaved to produce a mature polypeptide trafficked to lysosomes; CLN5 can undergo mannose-6-phosphate receptor-independent trafficking to lysosomes; all analyzed disease mutations disturb lysosomal trafficking of CLN5 but the degree of lysosomal targeting does not correlate with disease onset, suggesting CLN5 may also function outside lysosomes.\",\n      \"method\": \"Stable and transient expression, immunofluorescence localization, western blotting, treatment with M6P receptor inhibitors\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — stable expression systems with multiple mutants, M6P-independent trafficking demonstrated pharmacologically\",\n      \"pmids\": [\"20052765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CLN5-deficient fibroblasts show reduced ceramide, sphingomyelin, and glycosphingolipid levels; CLN8 protein corrects growth and apoptosis defects in CLN5-deficient cells; co-immunoprecipitation with CerS1 and absence of γ-actin from the CerS1 protein complex in CLN5-deficient cells suggest CLN5 functions as an activator of ceramide synthases.\",\n      \"method\": \"Lipid mass spectrometry, co-immunoprecipitation, differential gel electrophoresis, complementation assays\",\n      \"journal\": \"Electrophoresis\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP, complementation data suggestive but indirect for CLN5 as ceramide synthase activator\",\n      \"pmids\": [\"23160995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CLN5 loss causes impairment of mitochondrial functions; a mitochondria-focused quantitative proteomics approach revealed impaired autophagy machinery and altered mitophagy activation; these mitochondrial defects were confirmed in CLN5 KO cell models and Cln5-/- cerebral cortex and correlated with disease progression.\",\n      \"method\": \"Quantitative proteomics (mitochondria-enriched fractions), immunofluorescence, mitochondrial respiration assays, flow cytometry, patient fibroblast validation\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — quantitative proteomics plus functional assays across multiple models, 28 citations\",\n      \"pmids\": [\"32257390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CLN5-deficient human neurons (generated by CRISPRi in iPSC-derived cortical neurons) show reduced acidic organelles, reduced lysosomal enzyme activity, and impaired lysosomal movement — the first report of lysosomal trafficking defects in CLN5 disease.\",\n      \"method\": \"CRISPRi knockdown, live microscopy, flow cytometry, lysosomal enzyme activity assays, lysosomal tracking\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPRi KD in human neurons with multiple functional readouts in a relevant cell type\",\n      \"pmids\": [\"34680045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The mouse Cln5 gene product is a soluble lysosomal glycoprotein expressed in the developing brain, with prominent expression in cerebellar Purkinje cells, cerebral neurons, and hippocampal cells; expression pattern correlates with CNS regions that degenerate in CLN5 patients.\",\n      \"method\": \"In situ hybridization, immunohistochemistry, in vitro expression in COS-1, HeLa, and neuronal cells\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization by immunohistochemistry plus in vitro expression characterization, 53 citations\",\n      \"pmids\": [\"15207259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Cln5-/- mice show loss of vision, accumulation of autofluorescent storage material in CNS and peripheral tissues, prominent loss of GABAergic interneurons in multiple brain areas, and downregulation of myelin structural components; transcript profiling revealed altered expression of genes involved in neurodegeneration and immune/defense responses.\",\n      \"method\": \"Targeted gene deletion (exon 3), electron microscopy, immunohistochemistry, transcript profiling\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO mouse model with defined cellular phenotypes across multiple brain regions, 71 citations\",\n      \"pmids\": [\"15459177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Cln5 deficiency in mice leads to early and significant microglial activation (by 3 months), defective myelination in vitro and in developing brain, early alterations in serum lipid profiles, and dysfunctional lipid transport; Cln5 is most highly expressed in microglia.\",\n      \"method\": \"Gene expression analysis, in vitro myelination assays, microglial activation immunostaining, serum lipid profiling\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays in Cln5 KO model with mechanistic readouts, 43 citations\",\n      \"pmids\": [\"22182690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss of Cln5 in mice results in increased neural progenitor cell (NPC) proliferation, reduced NPC migration, and increased neuronal differentiation; neurite outgrowth was compromised in Cln5-/- cortical neurons; impaired interneuron development was linked to increased REST/NRSF binding to the Gad1 locus, reducing GAD67 (rate-limiting enzyme in GABA synthesis) expression.\",\n      \"method\": \"Embryonic brain analysis, BrdU proliferation assay, chromatin immunoprecipitation, primary cortical cultures, EEG\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating REST binding to Gad1, combined with cellular assays in KO model\",\n      \"pmids\": [\"31294445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In the Cln5-/- mouse, neuron loss begins in the cortex and only subsequently occurs in thalamic relay nuclei, in marked contrast to other NCL models where neuron loss begins in the thalamus; this is preceded by early and localized glial responses in the thalamocortical system.\",\n      \"method\": \"Stereological analysis, immunohistochemistry, quantitative cell counting across disease progression stages\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic stereological analysis defining pathway position and sequence of neurodegeneration, 37 citations\",\n      \"pmids\": [\"19385065\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CLN5 encodes a soluble lysosomal glycoprotein that functions as the BMP (bis(monoacylglycero)phosphate) synthase, catalyzing BMP biosynthesis via an energy-independent base exchange reaction between two LPG molecules; it also has cysteine palmitoyl thioesterase (S-depalmitoylase) activity mediated by a catalytic triad (Cys280-His166-Glu183); CLN5 is processed from a type II transmembrane precursor by SPPL3 into a mature soluble form anchored to the lysosomal lumen via an amphipathic helix; it interacts with multiple NCL proteins (CLN1-3, CLN6, CLN8) and regulates endolysosomal trafficking by functioning in a complex with CLN3 to control RAB7A-dependent retromer recruitment, endolysosome fusion, and lysosomal sorting receptor stability; CLN5 protein levels are controlled by KCTD7-mediated CUL3 ubiquitin ligase-dependent proteasomal degradation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CLN5 is a soluble lysosomal glycoprotein that functions as the BMP (bis(monoacylglycero)phosphate) synthase, catalyzing an energy-independent base exchange reaction between two lysophosphatidylglycerol molecules, and additionally possesses cysteine palmitoyl thioesterase (S-depalmitoylase) activity mediated by a Cys280-His166-Glu183 catalytic triad within an NlpC/P60 superfamily fold [PMID:37708259, PMID:35427157]. Synthesized as a type II transmembrane precursor, CLN5 is cleaved by the intramembrane protease SPPL3 to yield a mature soluble form (residues 93–407) that is retained in the lysosomal lumen via an amphipathic helix and trafficked through both mannose-6-phosphate receptor-dependent and -independent pathways [PMID:28442266, PMID:24038957, PMID:20052765]. CLN5 forms an endolysosomal complex with CLN3 that controls RAB7A-dependent retromer recruitment, endolysosome fusion, and stability of the sorting receptors sortilin and CI-MPR; its protein levels are regulated by KCTD7–CUL3 ubiquitin ligase-mediated proteasomal degradation, and excess CLN5 disrupts CLN6/CLN8-dependent ER-to-Golgi trafficking of lysosomal enzymes [PMID:34060589, PMID:22431521, PMID:35921411]. Loss-of-function mutations in CLN5 cause Finnish variant late infantile neuronal ceroid lipofuscinosis (vLINCL), characterized by accumulation of autofluorescent storage material and progressive cortical neurodegeneration [PMID:9662406, PMID:15459177].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Positional cloning established CLN5 as a novel disease gene, answering the molecular basis of Finnish variant late infantile neuronal ceroid lipofuscinosis and enabling all subsequent functional studies.\",\n      \"evidence\": \"Linkage analysis and mutation sequencing in Finnish vLINCL families identified three causative mutations\",\n      \"pmids\": [\"9662406\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No protein characterization or subcellular localization\", \"Function of the gene product entirely unknown\", \"Original transmembrane topology prediction was later revised\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Biochemical and localization studies overturned the initial transmembrane protein prediction, establishing CLN5 as a soluble lysosomal glycoprotein that physically interacts with CLN2 and CLN3, placing it within the NCL protein network.\",\n      \"evidence\": \"Confocal microscopy, deglycosylation, and reciprocal co-immunoprecipitation plus in vitro binding assays in BHK-21 and COS-1 cells\",\n      \"pmids\": [\"11971870\", \"12134079\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymatic function unknown\", \"Molecular basis for interactions with CLN2/CLN3 undefined\", \"Contribution of different initiator methionines to function unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"The Cln5 knockout mouse recapitulated human disease features—storage material accumulation, cortical neurodegeneration, and vision loss—providing a functional model and demonstrating that CLN5 is essential for neuronal survival in defined brain regions.\",\n      \"evidence\": \"Targeted exon 3 deletion in mice; electron microscopy, immunohistochemistry, and transcript profiling\",\n      \"pmids\": [\"15459177\", \"15207259\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biochemical substrate or enzymatic activity of CLN5 still unknown\", \"Mechanism linking CLN5 loss to storage material accumulation undefined\", \"Why certain neuron populations are selectively vulnerable unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Expanding the NCL interactome, CLN5 was shown to interact with CLN1/PPT1, CLN6, and CLN8, and the distinctive cortex-first pattern of neurodegeneration in Cln5−/− mice was delineated, distinguishing CLN5 disease pathology from other NCL subtypes.\",\n      \"evidence\": \"Co-immunoprecipitation for interaction network; stereological analysis of neurodegeneration across disease stages in Cln5−/− mice\",\n      \"pmids\": [\"19941651\", \"19385065\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional significance of each NCL protein interaction not resolved\", \"Whether interactions are direct or within larger complexes not determined for all partners\", \"Molecular link between CLN5 and neurodegeneration pattern unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"CLN5 was positioned as a regulator of endosomal sorting: its depletion reduced GTP-Rab7 and caused degradation of lysosomal sorting receptors sortilin and CI-MPR through defective retromer recruitment, providing the first mechanistic link between CLN5 and membrane trafficking.\",\n      \"evidence\": \"siRNA knockdown in HeLa cells with co-immunoprecipitation, Rab7 activation assay, and retromer recruitment analysis\",\n      \"pmids\": [\"22431521\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CLN5 acts directly on Rab7 or via an intermediary unknown\", \"How CLN5 enzymatic activity relates to retromer function not established\", \"Lipid perturbations in CLN5-deficient cells observed but not explained mechanistically\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"The biosynthetic processing of CLN5 was resolved: it is synthesized as a type II transmembrane protein whose N-terminal and TM domains are removed, yielding a soluble luminal protein anchored by an amphipathic helix; all eight N-glycosylation sites are utilized with differential roles in folding versus lysosomal targeting.\",\n      \"evidence\": \"Systematic mutagenesis of glycosylation sites and topology mapping with protease protection in transfected cells\",\n      \"pmids\": [\"24038957\", \"24058541\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the protease generating the mature form not yet established\", \"Whether amphipathic helix mediates membrane interactions relevant to enzymatic function unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Two key advances: SPPL3 was identified as the intramembrane protease cleaving CLN5's transmembrane precursor to generate the mature soluble form, and the first enzymatic activity—glycoside hydrolase activity—was demonstrated for both Dictyostelium and human CLN5.\",\n      \"evidence\": \"SPPL family overexpression/inhibitor studies; glycoside hydrolase assay with purified protein and mass spectrometry-based interactomics\",\n      \"pmids\": [\"28442266\", \"29128403\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological glycoside hydrolase substrates not identified\", \"Whether glycoside hydrolase activity is the primary function in mammalian lysosomes unknown\", \"SPPL3 cleavage not yet demonstrated with endogenous expression levels\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"CLN5 and CLN3 were shown to form a functional endolysosomal complex that controls RAB7A interactions with effectors and endolysosome fusion, directly linking CLN5 to the autophagy–lysosomal degradation axis and explaining trafficking defects in disease.\",\n      \"evidence\": \"CRISPR knockout, co-immunoprecipitation, endosome fusion assays, and CRISPRi in iPSC-derived neurons\",\n      \"pmids\": [\"34060589\", \"34680045\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structure of CLN3–CLN5 complex unknown\", \"Whether enzymatic activity of CLN5 is required for complex function not tested\", \"Relative contributions of BMP synthesis versus trafficking roles to disease pathology unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The crystal structure revealed CLN5 as an NlpC/P60 superfamily thioesterase with S-depalmitoylase activity via a Cys280-His166 catalytic dyad, and independently, CLN5 was identified as a substrate of the CRL3-KCTD7 ubiquitin ligase whose turnover controls ER-to-Golgi trafficking of lysosomal enzymes via CLN6/CLN8.\",\n      \"evidence\": \"X-ray crystallography and fluorescent thioesterase assay with active-site mutagenesis; ubiquitination assays and KCTD7 knockout cell analysis\",\n      \"pmids\": [\"35427157\", \"35921411\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological depalmitoylation substrates not identified\", \"Whether thioesterase and BMP synthase activities use the same active site not resolved\", \"Structural basis of KCTD7-CLN5 recognition unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"CLN5 was definitively identified as the lysosomal BMP synthase, resolving a decades-long search for this enzyme: it catalyzes BMP synthesis via energy-independent transacylation between two LPG molecules, and its loss causes massive LPG accumulation with BMP depletion.\",\n      \"evidence\": \"Lipidomics of CLN5 knockout cells and in vitro enzymatic reconstitution with purified protein\",\n      \"pmids\": [\"37708259\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BMP synthesis deficiency leads to the storage material accumulation and neurodegeneration not mechanistically defined\", \"Whether BMP synthase and thioesterase activities are independent or share a catalytic mechanism unresolved\", \"Regulation of BMP synthase activity in vivo poorly understood\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include: the relationship between CLN5's dual enzymatic activities (BMP synthase and thioesterase), identification of physiological depalmitoylation substrates, and how loss of BMP synthesis drives the selective neuronal vulnerability characteristic of CLN5 disease.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No study has tested whether the same catalytic site mediates both BMP synthesis and depalmitoylation\", \"Endogenous thioesterase substrates remain unidentified\", \"Mechanism linking BMP depletion to storage material formation and neurodegeneration not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [9, 12, 14]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [12, 15]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [14]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [1, 5, 6, 14, 16, 20]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [6, 13]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [4, 11]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [4, 11, 16]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [14, 17]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [11, 18]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 21]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"complexes\": [\n      \"CLN3-CLN5 endolysosomal complex\",\n      \"CRL3-KCTD7 (as substrate)\"\n    ],\n    \"partners\": [\n      \"CLN3\",\n      \"CLN2\",\n      \"CLN1\",\n      \"CLN6\",\n      \"CLN8\",\n      \"KCTD7\",\n      \"SPPL3\",\n      \"SORT1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}